Evaluation of Interferon-Lovastatin Therapy for Malignant Melanoma

This study has been withdrawn prior to enrollment.
(Modifications will be necessary before full IRB approval will be secured.)
Sponsor:
Information provided by:
NeoPlas Innovation
ClinicalTrials.gov Identifier:
NCT00963664
First received: August 20, 2009
Last updated: September 4, 2009
Last verified: September 2009

August 20, 2009
September 4, 2009
December 2009
December 2016   (final data collection date for primary outcome measure)
  • Overall survival [ Time Frame: 6 months, 1 yr, 2 yr, 3 yr, 4 yr, 5 yr ] [ Designated as safety issue: No ]
  • Time to progression of disease [ Time Frame: 2 mos, 4 mos, 6 mos, 1 yr, 2 yr, 3 yr, 4 yr, 5 yr ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00963664 on ClinicalTrials.gov Archive Site
  • Appearance of new distant metastases [ Time Frame: 2 mos, 4 mos, 6 mos, 1 yr, 2 yr, 3 yr, 4 yr, 5 yr ] [ Designated as safety issue: No ]
  • Toleration of medication side effects and quality of life [ Time Frame: 4 mos, 1 yr, 2 yr, 3 yr, 4 yr, 5 yr ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Evaluation of Interferon-Lovastatin Therapy for Malignant Melanoma
Phase 2 Study of Interferon Alfa-2b and Lovastatin Combination Therapy for Patients With High-risk Resected or Unresectable Malignant Melanoma

The purpose of this study is to determine whether an outpatient combination of lovastatin and low-to-moderate dose interferon is effective in the treatment of patients with malignant melanoma.

Malignant melanoma, or simply melanoma, is a potentially fatal cancer which begins as a skin cancer and can spread very aggressively. The incidence of melanoma has been rising rapidly over the last decade and it is now becoming a serious health threat in young adults as well as older adults. Unfortunately, if melanoma escapes complete surgical removal, there are very few treatments which have been found very effective in controlling its growth and spread. If the cancer spreads to the lymph node system or beyond, the chances for long-term survival can be very poor.

This study proposes to test the effectiveness for melanoma treatment of a combination of two medicines which are in widespread use for other medical conditions. Interferon alfa-2b (also known simply as interferon or by a brand name Intron-A) is an exact replica of a protein produced by the human immune system. The human body makes this immune system regulator to help it kill cells in the body which are damaged or infected and thus need to be removed before they can cause further harm to the body. This medicine is often prescribed for infections like hepatitis, some types of cancer including melanoma, and immune system disorders. This study uses interferon in moderate doses, much less than typically used for melanoma treatment when it is used alone, and so the side effects of treatment may be milder. The other medicine being used in combination with it is lovastatin. This medicine is most often used to help patients reduce their cholesterol levels and therefore reduce the risk of heart attacks and strokes. Millions of people use this medicine because it has been found very safe and effective. Research has shown that it also has significant effects against the growth of cancer cells in laboratory cultures and in some animal models.

These two medicines have been used together to treat patients with cancer for several years in our medical practice, but until now they have not been formally tested in a clinical trial. This study will test how well the combination of these medicines can perform and test the hypothesis that they can achieve better survival and control of disease than currently available standard treatment. The incidence of side effects and other details will be monitored too.

This study is open to qualifying patients with stage 2, 3, or 4 melanoma. The results for patients in each group will be compared to other patients in the study with the same or similar stage of disease and with historical results of patients receiving the standard, already-approved treatments for similar stages of melanoma.

Interventional
Phase 2
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Melanoma
  • Malignant Melanoma
  • Drug: lovastatin
    lovastatin tablets, oral administration, daily dose 1.5 mg/kg, divided into three or four essentially equal doses with meals
    Other Name: Mevacor
  • Drug: interferon alfa-2b
    interferon alfa-2b for subcutaneous injection, each injection 100,000 international units per kg body mass, three injections weekly
    Other Name: Intron-A
Experimental: Interferon and lovastatin treatment
Patients receive outpatient treatment with lovastatin (oral) and interferon alfa-2b (subcutaneous injection) as per protocol parameters.
Interventions:
  • Drug: lovastatin
  • Drug: interferon alfa-2b
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Withdrawn
250
December 2016
December 2016   (final data collection date for primary outcome measure)

Inclusion Criteria: (patients must meet all these criteria)

  • Histologically confirmed diagnosis of malignant melanoma
  • AJCC stage 2, 3, or 4 disease subject to the planned patient enrollment numbers for this trial
  • Surgical resection to the extent possible
  • ECOG performance status of 0, 1, or 2
  • Expected survival of six months or greater
  • ALT (SGPT) and AST (SGOT) not greater than 2.5x upper limit of normal range
  • CT, PET or other valid imaging sufficient to demonstrate extent of disease performed less than three weeks prior to initiation or less than two weeks following initiation
  • Female patients of childbearing potential must agree to practice contraception, abstinence, or other effective pregnancy avoidance measures while enrolled in this trial and for one month afterward

Exclusion Criteria: (patients meeting any of these criteria are ineligible)

  • Current or anticipated pregnancy or breastfeeding
  • History of or evidence suggestive of cerebral metastatic disease
  • Impaired ability to absorb nutrition and/or medications normally via gastrointestinal tract
  • Less than 18 years of age
  • History or evidence of cirrhosis, chronic hepatitis, pancreatitis, or other significant hepatobiliary impairment
  • History or evidence of HIV infection or other immune system impairment
  • History of organ or tissue transplant requiring immunosuppressive therapy
  • History of neutropenia other than that induced by chemotherapy
  • Cytotoxic chemotherapy or radiation treatment within three weeks prior to initiation
  • Presence of greater than six identifiable tumors counting all primary and metastatic lesions
  • Presence of any single tumor mass greater than 6 cm in greatest dimension
  • Presence of three or more tumor masses greater than 4 cm in greatest dimension
  • Chronic steroid or immunosuppressive therapy
  • Any other serious medical condition which, in the medical opinion of the investigator, limits life expectancy to two years or less or has significant potential for debilitation
  • Any condition, psychiatric or otherwise, which may preclude valid informed consent or consistent compliance with study requirements in the medical opinion of the investigator
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00963664
NI-MM-009
No
Stephen B. Cantrell MD, Director of Research, NeoPlas Innovation
NeoPlas Innovation
Not Provided
Principal Investigator: Stephen B. Cantrell, MD NeoPlas Innovation
NeoPlas Innovation
September 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP